Apellis (NASDAQ: APLS) holder files Form 144 for 2,892-share stock sale

Rhea-AI Filing Summary

A holder of Apellis Pharmaceuticals (APLS) common stock has filed a notice under Rule 144 to sell restricted shares. The filing covers the planned sale of 2,892 common shares through Fidelity Brokerage Services on NASDAQ around 01/20/2026, with an indicated aggregate market value of $57,241.07. These shares were acquired from the issuer as restricted stock vesting on 01/16/2026 as compensation.

The notice also lists prior sales of the issuer’s common stock during the past three months by the same seller: 10,000 shares on 10/21/2025 for gross proceeds of $280,300.00, and 3,856 shares on 01/13/2026 for gross proceeds of $85,553.84. The filing notes that there were 126,525,218 common shares outstanding at the time indicated.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2892	57241.07	126525218	01/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/16/2026	Restricted Stock Vesting	Issuer			2892	01/16/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Timothy E. Sullivan 100 Fifth Avenue Waltham MA 02451	Common	10/21/2025	10000	280300.00
Timothy E. Sullivan 100 Fifth Avenue Waltham MA 02451	Common	01/13/2026	3856	85553.84

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the latest Apellis (APLS) Form 144 filing disclose?

The Form 144 discloses a planned sale under Rule 144 of 2,892 Apellis common shares on or about 01/20/2026 through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $57,241.07.

How were the 2,892 Apellis (APLS) shares in the Form 144 acquired?

The 2,892 common shares were acquired on 01/16/2026 from the issuer as restricted stock vesting, identified as compensation rather than a cash purchase.

What Apellis (APLS) stock sales in the past 3 months are listed in this Form 144?

The filing lists two recent sales of Apellis common stock by the same seller: 10,000 shares on 10/21/2025 for gross proceeds of $280,300.00, and 3,856 shares on 01/13/2026 for gross proceeds of $85,553.84.

How many Apellis (APLS) shares are reported as outstanding in the Form 144 excerpt?

The securities information section reports 126,525,218 common shares outstanding for Apellis Pharmaceuticals at the time indicated in the filing.

Which broker and exchange are involved in the planned Apellis (APLS) Rule 144 sale?

The planned sale of 2,892 Apellis common shares is listed through Fidelity Brokerage Services LLC, with the securities to be sold on the NASDAQ exchange.

Who is the seller named in the recent Apellis (APLS) Form 144 transactions?

The section on securities sold during the past three months identifies Timothy E. Sullivan, with an address at 100 Fifth Avenue, Waltham, MA 02451, as the seller of the Apellis common shares listed.